Literature DB >> 26713662

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009.

Matthew J Soeberg1,2, Nicola Creighton3, David C Currow3, Jane M Young1, Nico van Zandwijk2.   

Abstract

INTRODUCTION: Malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPeM) are often grouped together in descriptive epidemiological analyses, resulting in limited understanding of epidemiological patterns for these tumour types.
METHODS: We studied patterns in the incidence, mortality and survival of people diagnosed with MPM (n=4,076) and MPeM (n=293) in New South Wales (NSW), Australia, 1972-2009. We also calculated 5-year relative survival for people diagnosed 1972-2006 followed up to 2007. We assessed patterns for each tumour type and histological subtype and, where possible, by combination of these categories.
RESULTS: Annual MPM cases steadily increased over time (n=208 in 2009). There was an increasing trend in the MPM age-standardised incidence rate from 1972 up to 1994. This rate increase has levelled off in the past 10 years. Since 1999, 11 cases of MPeM were diagnosed each year, on average. Five-year relative survival remained stable for MPM and MPeM. However, 5-year relative survival in 2002-2006 was substantially higher for people with MPM epithelioid histological subtype (11.7% [95%CI 6.8-18.2%]) compared to all other non-epithelioid histological subtypes (6.9% [95%CI 5.0-9.1%]), a 70% difference. Survival was also greater for women with MPM (13.4% [95%CI 8.5-19.4%]) compared to men (7.0% [95%CI 5.1-9.2%]).
INTERPRETATION: MPM incidence rates have stabilised since the mid-1990s, suggesting that maximum incidence levels have been reached. When more up-to-date data are available, survival estimates should be reanalysed to include people likely to benefit from the wide introduction of combination chemotherapy in 2007, including pemetrexed.
© 2015 Public Health Association of Australia.

Entities:  

Keywords:  Australia; incidence; malignant mesothelioma; mortality; peritoneal; pleural; relative survival

Mesh:

Year:  2015        PMID: 26713662     DOI: 10.1111/1753-6405.12503

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  4 in total

1.  Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.

Authors:  David B Chapel; Jefree J Schulte; Gudrun Absenger; Richard Attanoos; Luka Brcic; Kelly J Butnor; Lucian Chirieac; Andrew Churg; Françoise Galateau-Sallé; Kenzo Hiroshima; Yin P Hung; Hedy Kindler; Thomas Krausz; Alberto Marchevsky; Mari Mino-Kenudson; Jeffrey Mueller; Kazuki Nabeshima; Kirin Turaga; Ann E Walts; Aliya N Husain
Journal:  Mod Pathol       Date:  2020-10-15       Impact factor: 7.842

2.  Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.

Authors:  David B Chapel; Jason L Hornick; Julianne Barlow; Raphael Bueno; Lynette M Sholl
Journal:  Mod Pathol       Date:  2022-04-22       Impact factor: 8.209

3.  Gender Differences in Outcomes of Patients With Mesothelioma.

Authors:  Naomi Alpert; Maaike van Gerwen; Raja Flores; Emanuela Taioli
Journal:  Am J Clin Oncol       Date:  2020-11       Impact factor: 2.787

4.  Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.

Authors:  Nadine L de Boer; Job P van Kooten; Ronald A M Damhuis; Joachim G J V Aerts; Cornelis Verhoef; Eva V E Madsen
Journal:  Ann Surg Oncol       Date:  2019-10-16       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.